Biology Reference
In-Depth Information
A phase I study (NCT00656825) designed to evaluate tolerability and bioavail-
ability of P144 peptide, which blocks the interaction between ligand and type RIII
in healthy subjects, has been reported. The P144 peptide covers amino acid residues
730-743 (TSLDASIIWAMMQN) of the ligand binding external domain of the RIII
receptor. This peptide inhibitor is also being investigated for its safety and efficacy
by topical application in patients with skin fibrosis related to systemic sclerosis
(NCT00574613). There are many experimental studies on the effects of this peptide
on fibrosis, but these have not been discussed here on criteria of relevance.
Search WWH ::
Custom Search